Literature DB >> 12457271

Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.

Carl L Hart1, Amie S Ward, Margaret Haney, Sandra D Comer, Richard W Foltin, Marian W Fischman.   

Abstract

RATIONALE: Although smoked marijuana contains at least 60 cannabinoids, delta(9)-tetrahydrocannabinol (delta(9)-THC) is presumed to be the cannabinoid primarily responsible for many marijuana-related effects, including increased food intake and subjective effects. Yet, there has been no systematic comparison of repeated doses of oral delta(9)-THC with repeated doses of smoked marijuana in the same individuals.
OBJECTIVE: To compare the effects of oral delta(9)-THC and smoked marijuana in humans under controlled laboratory conditions.
METHODS: Eleven healthy research volunteers, who reported smoking an average of six marijuana cigarettes per day, completed an 18-day residential study. Marijuana cigarettes (3.1% delta(9)-THC, q.i.d.) were smoked or delta(9)-THC (20 mg, q.i.d.) was taken orally using a staggered, double-blind, double-dummy procedure for three consecutive days. Four days of placebo administration separated each active drug condition. Psychomotor task performance, subjective effects, and food intake were measured throughout the day.
RESULTS: Relative to placebo baseline, oral delta(9)-THC and smoked marijuana produced similar subjective-effect ratings (e.g., "high" and "mellow"), although some effects of smoked marijuana were more pronounced and less prone to the development of tolerance. Additionally, participants reported "negative" subjective effects (e.g., "irritable" and "miserable") during the days after smoking marijuana but not after oral delta(9)-THC. Both drugs increased food intake for 3 days of drug administration, but had little effect on psychomotor performance.
CONCLUSION: These results indicate that the behavioral profile of effects of smoked marijuana (3.1% delta(9)-THC) is similar to the effects of oral delta(9)-THC (20 mg), with some subtle differences.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12457271     DOI: 10.1007/s00213-002-1231-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  60 in total

1.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Authors:  Shanna Babalonis; Margaret Haney; Robert J Malcolm; Michelle R Lofwall; Victoria R Votaw; Steven Sparenborg; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-12-14       Impact factor: 4.492

2.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

Review 3.  The marijuana withdrawal syndrome: diagnosis and treatment.

Authors:  Margaret Haney
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 4.  [Palliative pain therapy, cannabinoids].

Authors:  L Radbruch; F Elsner
Journal:  Internist (Berl)       Date:  2005-10       Impact factor: 0.743

5.  Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

Authors:  Diana L McKinney; Michael P Cassidy; Lauren M Collier; Billy R Martin; Jenny L Wiley; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

6.  Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.

Authors:  Jennifer N Gray; Alison B Breland; Michael Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2008-09       Impact factor: 4.244

7.  Smoked marijuana attenuates performance and mood disruptions during simulated night shift work.

Authors:  Diana R Keith; Erik W Gunderson; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Drug Alcohol Depend       Date:  2017-06-28       Impact factor: 4.492

8.  The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.

Authors:  Mohammed A Issa; Sanjeet Narang; Robert N Jamison; Edward Michna; Robert R Edwards; David M Penetar; Ajay D Wasan
Journal:  Clin J Pain       Date:  2014-06       Impact factor: 3.442

9.  Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia.

Authors:  Maria Scherma; Valentina Satta; Roberto Collu; Maria Francesca Boi; Paolo Usai; Walter Fratta; Paola Fadda
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

Review 10.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.